Bristol admilparant Phase 3 IPF win lifts Contineum pre-market on LPA1 readthrough

 

BMS admilparant Phase 3 IPF win lifts Contineum 21% pre-market on LPA1 readthrough

• Bristol Myers Squibb announced Monday that Phase 3 ALOFT-IPF of LPA1 antagonist admilparant met its primary FVC endpoint.
• The 60 mg dose showed statistically significant FVC improvement versus placebo at week 52; 120 mg slowed decline without significance.
• Safety was well tolerated with adverse-event discontinuations similar to placebo, easing prior liver-toxicity class concerns.
• Contineum's lead PIPE-791 is a once-daily LPA1 antagonist in Phase 2 for idiopathic pulmonary fibrosis, making this a class-validating readthrough.
• Analysts including Stifel had flagged the BMS readout as a potential derisking event for Contineum's IPF program.
• The news hit around 5:55 AM ET per Reuters, driving the pre-market gap from Friday's $13.38 close.
• No Contineum press release or SEC filing appeared; Finviz listed no ticker-specific headline since the prior close.

https://finviz.com/stock?t=CTNM&p=d